Provides a cloud-based software-as-a-service (SaaS) research platform. Facilitates the transactional sale of scientific, technical, and medical (STM) content. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
If every debt were paid off today, $12.6M would still be left in the vault — a solid cushion for hard times.
The market pays 25.4× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 82% of them.
Analysts' average target sits 79% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 48% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 10% a year on average.
There is $12.6M in the vault; even if every debt were paid off, $12.6M would remain.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 40/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, RSSS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: RSSS is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.